 Connection
Jarratt Pytell to Opioid-Related Disorders
This is a "connection" page, showing publications Jarratt Pytell has written about Opioid-Related Disorders.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.065 |
|
|
|
-
Pytell JD, Christine PJ, LeMasters K, Rockhill KM, Black JC, Dart RC, Binswanger IA. Comparison of heroin and fentanyl use in US nationally representative surveys. Addict Sci Clin Pract. 2025 Feb 11; 20(1):13.
Score: 0.550
-
Pytell JD, Binswanger IA. Addressing Opioid Use Disorder in Primary Care: Revisiting Core Primary Care Principles to Confidently Initiate Treatment. J Gen Intern Med. 2024 Jul; 39(9):1749-1750.
Score: 0.517
-
Pytell JD, Fojo AT, Keruly JC, Snow LN, Falade-Nwulia O, Moore RD, Chander G, Lesko CR. Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use. Addict Sci Clin Pract. 2023 09 02; 18(1):51.
Score: 0.497
-
Pytell JD, Rubenstein LV. So What Do We Do Now? New Opioid Prescribing Guidelines, Implementation Science, and How to Improve the Care of Patients Receiving Long-Term Opioid Therapy in Primary Care. J Gen Intern Med. 2023 06; 38(8):1791-1793.
Score: 0.489
-
Pytell JD, Whitley P, Passik SD, Bundy WL, Dawson E, Saloner B. Association of Patients' Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder. JAMA Psychiatry. 2023 05 01; 80(5):459-467.
Score: 0.486
-
Pytell JD, Chander G, Thakrar AP, Ogunwole SM, McGinty EE. Does a Survivorship Model of Opioid Use Disorder Improve Public Stigma or Policy Support? A General Population Randomized Experiment. J Gen Intern Med. 2023 05; 38(7):1638-1646.
Score: 0.471
-
Pytell JD, Sklar MD, Carrese J, Rastegar DA, Gunn C, Chander G. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder. J Gen Intern Med. 2022 02; 37(3):593-600.
Score: 0.425
-
Pytell JD, Rastegar DA. Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. J Subst Abuse Treat. 2021 01; 120:108155.
Score: 0.407
-
Pytell JD, Sharfstein JM, Olsen Y. Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities. JAMA Intern Med. 2020 01 01; 180(1):7-8.
Score: 0.386
-
Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019 12 19; 14(1):46.
Score: 0.385
-
Lesko CR, Falade-Nwulia OO, Pytell JD, Hutton HE, Fojo AT, Keruly JC, Moore RD, Chander G. Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019. Addiction. 2023 11; 118(11):2193-2202.
Score: 0.123
-
Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. J Subst Use Addict Treat. 2023 07; 150:209055.
Score: 0.121
-
Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Subst Abus. 2022; 43(1):633-639.
Score: 0.109
-
Callan J, Pytell J, Ross J, Rastegar DA. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study. J Addict Med. 2020 Sep/Oct; 14(5):e274-e276.
Score: 0.101
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|